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Abstract
Acute myeloid leukemia (AML) with mutated NPM1 accounts for one-third of newly diagnosed AML. Despite recent
advances, treatment of relapsed/refractory NPM1-mutated AML remains challenging, with the majority of patients
eventually dying due to disease progression. Moreover, the prognosis is particularly poor in elderly and unfit patients, mainly
because they cannot receive intensive treatment. Therefore, alternative treatment strategies are needed. Dactinomycin is a
low-cost chemotherapeutic agent, which has been anecdotally reported to induce remission in NPM1-mutated patients,
although its mechanism of action remains unclear. Here, we describe the results of a single-center phase 2 pilot study
investigating the safety and efficacy of single-agent dactinomycin in relapsed/refractory NPM1-mutated adult AML patients,
demonstrating that this drug can induce complete responses and is relatively well tolerated. We also provide evidence that
the activity of dactinomycin associates with nucleolar stress both in vitro and in vivo in patients. Finally, we show that low-
dose dactinomycin generates more efficient stress response in cells expressing NPM1 mutant compared to wild-type cells,
suggesting that NPM1-mutated AML may be more sensitive to nucleolar stress. In conclusion, we establish that
dactinomycin is a potential therapeutic alternative in relapsed/refractory NPM1-mutated AML that deserves further
investigation in larger clinical studies.
Introduction
The NPM1 gene encodes for a multifunctional nucleolar
chaperone [1, 2], that continuously shuttles between
nucleus and cytoplasm [3, 4]. NPM1 is mutated in
approximately one-third of newly diagnosed acute mye-
loid leukemia (AML) cases [5]. NPM1 mutations are
usually heterozygous insertions in the last exon of the
gene [5, 6] that cause the loss of the nucleolar localization
signal and generation of a novel nuclear export signal
[7, 8]. These changes result in aberrant delocalization of
the NPM1 mutant in the nucleoplasm and in the cyto-
plasm that is, in turn, responsible for leukemogenesis
through a yet unclear mechanism [9].
Because of its specific features [9], NPM1-mutated AML
has been included as distinct entity in the World Health
Organization (WHO) classification of lympho-
hematopoietic tumors [10]. Criteria for the diagnosis, risk
stratification and monitoring of measurable residual disease
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(MRD) of this AML entity are now well established [9–13].
Currently, its treatment still relies on standard chemother-
apy (CHT) plus a FLT3 inhibitor (only in cases with
mutated FLT3) with or without allogeneic hematopoietic
stem cell transplantation (allo-HSCT), depending on the
predicted relapse risk [11]. More recently, the combination
of venetoclax plus hypomethylating agents or low-dose
cytarabine [11, 14–16] has demonstrated promising clinical
activity, particularly in patients unfit for intensive CHT.
However, the majority of older patients with NPM1-muta-
ted AML eventually relapse and die of progressive disease,
clearly indicating that new therapeutic strategies are needed
for this AML entity.
Actinomycin D (dactinomycin) is known to inhibit RNA
Polymerase I (RNA Pol I) [17–19], depleting nucleoli of
ribosomal RNA (rRNA) and inducing nucleolar stress
response [20]. NPM1 is regarded as a nucleolar stress
sensor [9, 21]. Specifically, following RNA Pol I inhibition,
NPM1 is released [22] together with other nucleolar pro-
teins (e.g., ribosomal proteins) [23] from the nucleolus to
the nucleoplasm [20]. These molecules, including NPM1,
bind to and inhibit the ubiquitin-ligase HDM2 leading to the
consequent increase of TP53 levels.
We hypothesized that higher NPM1 levels in the
nucleoplasm of NPM1-mutated AML cells (secondary to
the aberrant localization of mutant NPM1 as well as,
through heterodimerization, of wild-type NPM1) may
facilitate nucleolar stress response and increase sensitivity
to dactinomycin in NPM1-mutated AML cells [24]. More-
over, TP53 genetic abnormalities are extremely rare in
NPM1-mutated AML [25, 26], implying that signals
downstream of nucleolar stress response are preserved in
leukemic cells, further supporting the use of dactinomycin
in this setting.
Dactinomycin is currently used, alone or in combina-
tion with other drugs, to treat different types of solid
tumors, both in adult and pediatric patients [27]. Main
side effects of dactinomycin include dose-dependent
myelosuppression, gastrointestinal and oral mucositis
and alopecia [27]. However, this drug is not cardiotoxic,
allowing its use in patients with cardiac impairment. In
this regard, we have previously described one patient with
NPM1-mutated AML unfit for intensive chemotherapy
because of concomitant heart failure and refractory to 5-
azacytidine, successfully treated with single-agent dacti-
nomycin [24]. Here, we report the results of a phase 2
pilot clinical trial of single-agent dactinomycin in a cohort
of 10 patients with relapsed or refractory (r/r) NPM1-
mutated AML (EudraCT n. 2014-000693-18). Addition-
ally, we define for the first time the pharmacokinetics of
dactinomycin in adult AML patients and provide insights




The study was a single-center, single-arm, open-label, phase
2 pilot study to evaluate the safety and efficacy of dacti-
nomycin in NPM1-mutated AML patients with hematolo-
gical relapse or refractory disease. Relapse was established
by morphological and immunohistochemical analysis (evi-
dence of cytoplasmic NPM1). The protocol flow-chart is
shown in Fig. 1A (for more details see Supplemental
Materials and Protocol Synopsis). The protocol was
approved by the Umbria Ethics Committee and the Italian
Drug Agency and registered at the European Union Clinical
Trial Register (clinicaltrialsregister.eu EudraCT n. 2014-
000693-18). All patients signed a written informed consent.
Dactinomycin was administered at 15 µg/kg/day for 5
consecutive days, which is the highest dose accepted
according to the AHFS Drug Information [27]. Our decision
to use slightly higher doses than those employed in gesta-
tional trophoblastic tumor (i.e., 10–12.5 µg/Kg/day for
5 days) [28] was based on the presumed higher aggres-
siveness of r/r NPM1-mutated AML. Administration of
dactinomycin for 5 consecutive days followed by an inter-
val of 2–4 weeks (depending on hematological and extra-
hematological toxicity) defined one cycle of therapy.
Response was evaluated after one or two cycles. Com-
plete response (CR) was defined as ≤5% BM leukemic cells
with normalization of blood counts (neutrophils > 1.5 × 109/
L, hemoglobin ≥10 g/dL, platelets > 100 × 109/L). CR with
incomplete marrow recovery (CRi) was defined as ≤5% BM
leukemic cells with incomplete recovery of blood counts.
Patients not achieving CR or CRi (CR/CRi) after cycle 1
received a second induction cycle, unless progressive dis-
ease occurred. Patients not achieving CR/CRi after two
cycles were withdrawn from the study. Patients achieving
CR/CRi were allowed to receive a maximum of six cycles.
Since in the original protocol criteria for response and
relapse differed from those recommended by the European
LeukemiaNet 2017 (ELN) [12], response and relapse rates
were also calculated applying the ELN criteria, with abso-
lutely no difference in the outcomes. Adverse events were
graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 4.03.
Clinical study statistical analysis
A Simon’s minimax two-stage design was adopted. We
calculated a sample size that would be sufficient to accept
the alternative hypothesis (CR/CRi rate after one or two
induction cycles, ≥45%) and reject the null hypothesis (CR/
CRi rate after one or two induction cycles, ≤10%), at an
alpha level of 0.05 and a beta level of 0.2. Enrollment was
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closed in February 2016, when the prespecified number of
patients (n= 10) had been enrolled. The study drug was to
be considered worth of further investigation if CR/CRi was
obtained in at least three patients.
Comparisons between multiple groups was done apply-
ing the Dunnett's multiple comparison test with an alpa
level of 0.05.
Pharmacokinetics studies
Blood samples for quantification of dactinomycin con-
centrations were collected in EDTA tubes prior to drug
administration and at 15, 30, 60, and 240 min post-
administration. Plasma was obtained from whole blood by
centrifugation at 1200 × g for 10 min at 4 °C and stored at
−80 °C prior to shipment to the Newcastle University
Centre for Cancer, UK for analysis. Dactinomycin levels
were quantified using a fully validated liquid
chromatography-mass spectrometry assay, with a limit of
quantification of 0.25 ng/mL, as previously described
[29, 30]. Briefly, extraction of clinical samples was car-
ried out with acetonitrile and analysis performed on an
API 4000 LC/MS/MS (AB SCIEX) using an
internal standard of 7-aminoActD. The method has been
demonstrated to exhibit good reproducibility over a cali-
bration curve range of 0.25–100 ng/mL, with intra- and
interassay precision and accuracy CVs and relative errors
of <15%.
In vitro experiments
Cell lines were purchased from the Leibniz Institute-DSMZ
(Braunschweig, Germany) except for IMS-M2, which
was kindly provided by Dr. Daniel G. Tenen (National Uni-
versity of Singapore, Singapore). Cells were cultured in RPMI
(IMS-M2, HNT-34) or alfa-MEM (OCI-AML3, OCI-AML2)
supplemented with 10% FBS, 1% penicillin–streptomycin,
and 1% glutamine. Cells from a NPM1-mutated AML patient-
derived xenograft model (PDX2) [31] and primary patient
samples were kept in IMDM supplemented with 10% FBS,
1% penicillin–streptomycin, and 1% glutamine. Cells were
exposed to dactinomycin at concentrations and time dura-
tions, as indicated. Cell viability was studied by flow cyto-
metry with Annexin V and 7-AAD. Aliquots of treated cells
were lysed for western blot analysis and aliquots were
cytospun for immunofluorescence. Number of biological
replicates is reported in figure legends.
Engineering of isogenic cell lines
OCI-AML2 cells expressing doxycycline-inducible
mutant NPM1 (NPM1mut) were engineered through lenti-
viral infection. pLVX-EF1a-Tet3G was used as regulator
vector and pLVX-TRE3G-ZsGreen1 was used as response
vector containing NPM1mut. Fresh doxycycline (100 ng/
ml) was used for NPM1mut induction. Cells were either left
untreated or treated with dactinomycin, as indicated.
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* If in CR/CRi, fit for allo-HSCT and donor available, patient sent to allo-HSCT as soon as possible.
Fig. 1 Dactinomycin can
induce CR/CRi in NPM1-
mutated AML patients. A
Schematic representation of the
study protocol. B Bone marrow
biopsies of patient UPN006
before and after induction.
Left panels are stained with
hematoxylin and eosin (H/E),
while right panels are stained
with an anti-NPM1 (tNPM1),
which recognizes both mutant
and wild-type NPM1 (APAAP
immunostaining, original
magnification ×400).
C Monitoring of NPM1mut
transcripts by reverse-
transcriptase real-time
quantitative PCR in 8 out of 10
patients included in the protocol.




transplant; R relapse, T
transplant, Resp. responders,
Non-resp. nonresponders.
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In vivo studies
BM aspiration was performed before starting (baseline) and
4 h following the first (day 1) and/or the fourth (day 4)
administration of dactinomycin. Aliquots of BM mono-
nucleated cells were used both for western blot analysis and
cytospin for immunofluorescence.
Targeted DNA sequencing
Genomic DNA was extracted from BM samples of 9/10
patients, prior to dactinomycin administration, using stan-
dard methods and subjected to molecularly-barcoded tar-
geted sequencing of 40 myeloid genes (QIAseq Targeted
DNA Custom Panel CDHS-13640Z-1017–QIAGEN). Tar-
geted sequencing was also performed following one or two
cycles of dactinomycin in the BM of 6/10 patients,
including 4/4 patients who achieved CR/CRi, and was used
to facilitate variant calling at diagnosis (see Supplemental
Materials). Libraries generated according to the manu-
facturer’s instructions were sequenced on an Illumina
MiSeq instrument, using MiSeq Reagent Kit v3 and V2.
Results
Single-agent dactinomycin demonstrates clinical
activity in r/r NPM1-mutated AML
Between June 2014 and February 2016, 10 patients aged
between 53 and 75 years (median 67) with r/r NPM1-
mutated AML, who fulfilled all inclusion criteria, were
enrolled onto the study. Patient characteristics are sum-
marized in Table 1. Of 10 patients included, eight had
relapsed disease (1–4 previous lines of treatment), and two
had refractory disease progressing upon either 5-azacytidine
or ‘7+ 3’ (Table 1). One patient (UPN004), who was
colonized by a multiresistant Klebsiella pneumoniae, died
early during induction 1 due to a septic shock caused by the
same microorganism and was not considered evaluable for
toxicity or response rate.
Four out of the nine evaluable patients achieved CR/CRi
after either one (UPN006, UPN008) or two (UPN005 and
UPN009) induction cycles (Table 1). Morphologic CR was
confirmed by immunohistochemistry [9], demonstrating the
absence of cells with cytoplasmic NPM1 (Fig. 1B). A sig-
nificant drop of NPM1 mutant transcript copies (median
2.36 log, range 2.1–2.7) was observed by quantitative PCR
analysis after two cycles in patients that achieved CR/CRi
(Fig. 1C). Nevertheless, a temporary disappearance of leu-
kemic cells from the PB was documented in all nine eva-
luable patients.
Patient UPN008 underwent haploidentical HSCT in CR
after four cycles of dactinomycin and is still alive 4.7 years
after transplant, with no detectable MRD measured by RT-
qPCR. The other three patients who obtained CR relapsed
after 3 (UPN005), 5 (UPN009), and 7 (UPN006) months. In
all cases, hematological relapse was anticipated by
increasing NPM1 mutant transcripts (Fig. 1C) and detection
of cytoplasmic NPM1 in BM blasts by immunohis-
tochemistry (not shown).
Grade 4 anemia, thrombocytopenia and neutropenia
consistently occurred during induction cycles, most likely
due to leukemic BM infiltration. Grade ≥3 hematologic
toxicities were also observed during consolidation cycles
but were usually manageable in an outpatient setting. In
fact, patients undergoing consolidation required only an
average of <1 red cell unit and <1 platelet unit per cycle
Table 1 Characteristics of R/R
NPM1-mutated AML patients
enrolled in the trial.
Patient Age Disease status Previous therapy FLT3 Response Response duration
UPN001 66 Relapsed CHT 2 lines FLT3-ITDhomo PD —
UPN002 66 Relapsed CHT 2 lines FLT3-ITDhomo PD —
UPN003 75 Relapsed CHT 1 line FLT3-ITDhomo PD —
UPN004 73 Relapsed CHT 1 line WT Early Death —
UPN005 71 Relapsed CHT 4 lines WT CR
(after 2 cycles)
3 months
UPN006 74 Refractory HMA WT CR
(after 1 cycle)
7 months
UPN007 53 Relapsed HMA WT PDa —
UPN008 63 Relapsed CHT/AuSCT WT CRi
(after 1 cycle)
4.7 yearsb
UPN009 66 Relapsed CHT 1 line FLT3-ITD CR
(after 2 cycles)
5 months
UPN010 67 Refractory CHT 1 line WT PDa —
WT wild-type, CHT cytotoxic chemotherapy, PD progressive disease, HMA hypomethylating agent, AuSCT
autologous peripheral blood stem cell transplantation, CR complete remission, CRi complete remission with
incomplete marrow recovery.
aResistant to a further intensive chemotherapy regimen (UPN007: ‘7+ 3; UPN010: FLAI).
bPatient still alive in CR after HSCT.
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(average 0.91 unit/cycle for both red cell and platelet units;
range 0–5 for red cell units, and 0–2 for platelet units).
Interestingly, in the four patients who underwent at least
two consolidation cycles, platelet nadir occurred at a med-
ian time of 11 days in both consolidation cycle 1 and
consolidation cycle 2 (range 11–22 for consolidation 1 and
9–12 for consolidation 2), while neutrophil nadir occurred
later at a median time of 17.5 days in consolidation 1 and
18 days in consolidation 2 (range 17–25 for consolidation 1
and 15–20 for consolidation 2).
Recurrent grade ≥3 extrahematologic toxicities were
limited to oral mucositis, febrile neutropenia and sepsis
(Table S1). Sepsis was reported only during the first cycle.
Oral mucositis was transient but particularly unpleasant for
patients, especially during the first cycle.
FLT3 mutations (FLT3-ITD) were identified in 4/10
patients (Tables 1 and 2). In 3 of them (UPN001, 002, and
003) FLT3-ITD was found at a variant allele frequency >0.5,
indicating homozygosity (FLT3-ITDhomo). Notably, no patient
carrying FLT3-ITDhomo achieved CR/CRi. To further estab-
lish the mutational profiles of patients enrolled in the study,
we performed targeted DNA sequencing of 40 genes recur-
rently mutated in myeloid neoplasms (Table S2) on the BM
sampled at the time of enrollment. Although the study was not
powered to find association between specific mutations and
response to treatment, 3/4 patients that achieved CR/CRi
carried concomitant IDH1 or IDH2 mutations.
These results demonstrate that single-agent dactinomycin
15 µg/kg/day for 5 consecutive days can induce CR in
relapsed/refractory NPM1-mutated AML. Oral mucositis
was the main limiting toxicity at this dosage.
Pharmacokinetics of dactinomycin
To establish the pharmacokinetics of dactinomycin in adult
patients with NPM1-mutated AML, we serially determined
drug plasma concentrations by mass spectrometry [30] in
nine patients. As previously reported in pediatric
Table 2 DNA variants detected
in patients at the time of
enrollment in the study.
Patient % Blasta FLT3 Gene VAF (%) HGVS protein sequence CR/CRi
UPN001 40–50 ITDb N.A. N.A. — No
UPN002 80 ITDb NPM1 38.94 p.Trp288CysfsTer12 No
DNMT3A 48.45 p.Arg882His
UPN003 40 ITDb NPM1 21 p.Trp288CysfsTer12 No
DNMT3A 30.15 p.Arg882His
RAD21 26.31 p.Arg586Ter
UPN004 80–90 WT NPM1 39.21 p.Trp288CysfsTer12 N.E.
DNMT3A 45.41 p.Arg882His
IDH1 43.25 p.Arg132His








UPN007 40–50 WT NPM1 17.06 p.Trp288CysfsTer12 No
GATA2 18.31 p.His380Gln
GATA2 1.3 p.Arg362Gly
UPN008 15–20 WT NPM1 /c /c Yes
IDH1 16.96 p.Arg132Ser
TET2 4.05 p.His1219Arg
UPN009 20 ITD NPM1 5.62c p.Trp288CysfsTer12 Yes
IDH1 4.66 p.Arg132His
UPN010 20–25 WT NPM1 /c /c No
BCORL1 2.05 p.Leu647Val
IDH1 1.26 p.Arg132His
N.A. not available, N.E. not evaluable, VAF variant allele frequency.
aBlast percentage on BM biopsy or aspirate, prior to treatment.
bFLT3-ITD VAF > 50%.
cSamples with marked peripheral blood contamination;/Variant frequency below the threshold for calling.
NPM1 mutations were confirmed in all patients by immunohistochemistry and by conventional molecular
techniques.
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populations [29], on day 1 Cmax values ranged between 12
and 34.4 ng/ml (Fig. 2A), clearance values ranged between
7.6 and 25.9 L/h (Fig. 2B) and AUC0-24h ranged between
2.0 and 4.3 mg/L.min (Fig. 2C) across the nine patients.
However, we registered a consistent and progressive
reduction of the drug clearance over the following 4 days of
treatment (Fig. 2B). This resulted in higher exposures to
dactinomycin on day 5 as compared to day 1, with AUC0-24h
values observed ranging from 3.5–6.6 mg/L.min at day 5
(Fig. 2C). Of note, UPN007 who had mild renal impairment
(estimated glomerular filtration rate 51 ml/min/1.73m [2]),
showed a marked reduction in drug clearance beginning at
day 2 and the highest AUC0–24h values (Fig. 2B, C). These
findings suggest that the dose or the treatment duration may
need to be reduced in patients with renal impairment.
Neither Cmax nor AUC0–24h values correlated with remis-
sion induction. However, we observed a correlation between
the severity of oral mucositis and dactinomycin plasma con-
centrations. In fact, grade 3 mucositis was observed in
UPN001, 002, 003 and 009, who reported AUC0–24h values
higher than other patients (except UPN007), suggesting that
decreasing the dose of dactinomycin may reduce the grade of
mucositis while retaining antileukemic activity.
Pulsed doses of dactinomycin induce nucleolar
stress in vitro and in vivo
To investigate whether the drug activity correlates with the
nucleolar stress response, we exposed NPM1-mutated
leukemic cells to pulsed doses dactinomycin in vitro. Based
on our PK studies and previously published data [17–19],
we incubated AML cells with dactinomycin concentrations
ranging between 0.005 and 0.1 μg/ml, for 1–6 h. The drug
was then washed out and AML cells were placed in fresh
medium. When appropriate, pulsed treatment was repeated
for up to 5 consecutive days, reproducing the schedule
adopted in patients.
We first tested our strategy in the NPM1-mutated AML
cell line OCI-AML3. One-hour/day exposure to dactino-
mycin induced progressive nucleolar changes (Fig. 3A),
indicative of nucleolar stress [32, 33]. Specifically, NPM1
diffused from the nucleoli to the nucleoplasm, with con-
comitant loss of the irregular nucleolar shape and gain of a
more spheroidal shape (Fig. 3A). Changes in NPM1 dis-
tribution became more evident over time, with a nearly
complete nucleoplasmic diffusion at 96 h (Fig. 3A). No
consistent changes in the distribution of cytoplasmic NPM1
were observed (not shown).
NPM1 can bind to and inhibit the ubiquitin-ligase
HDM2, one of the key regulators of TP53 levels [34, 35].
Dactinomycin-induced NPM1 diffusion to the nucleoplasm
is known to result in NPM1-HDM2 interaction and HDM2
inhibition, leading to increased TP53 levels [34, 35].
Indeed, changes in NPM1 nuclear distribution were asso-
ciated with a progressive increase in TP53 (Fig. 3B), fol-
lowed by dose-dependent cell death in OCI-AML3 cells
exposed to dactinomycin (Fig. 3C). This response pattern
























































































































Fig. 2 Pharmacokinetics of
dactinomycin. A Plasma
concentrations of dactinomycin
following the first administration
in each patient. B Dactinomycin
clearance during the 5 days of
treatment (cycle 1) in each
patient. C Dactinomycin
AUC0–24h during the 5 days of
treatment (cycle 1) in each
patient.
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different NPM1-mutated AML cell line (IMS-M2) [36]
(Fig. S1A and not shown).
To confirm that nucleolar stress response can be induced
in primary AML cells, we applied the same strategy to treat
fresh AML samples from two patients included in the study
(UPN002 and 004) (Fig. S1B, S1C, S1D, S1E) and from the
previously reported patient (Fig. S1F), demonstrating
consistent NPM1 diffusion to the nucleoplasm coupled with
increased TP53 levels.
Finally, to demonstrate that dactinomycin can elicit
nucleolar stress in patients, we performed sequential BM
aspiration at baseline, 4 h after the first administration (day
1) and 4 h following the fourth administration (day 4) in one
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nucleolar morphology, NPM1 nucleoplasmic diffusion and
increased TP53 levels (Fig. 3G, H). Early TP53 increase
(day 1) was also confirmed in the BM of a second patient
(UPN004) (Fig. S1G).
Altogether, these data demonstrate that pulsed dactino-
mycin induces nucleolar stress in NPM1-mutated AML
cells as early as 4 h both in vitro and in leukemic patients
undergoing treatment.
Differential nucleolar stress response in NPM1-
mutated versus NPM1 wild-type AML cells
To explore whether NPM1-mutated cells may have lower
thresholds for nucleolar stress response than NPM1 wild-
type cells, we exposed to dactinomycin OCI-AML3 and
IMS-M2 cells as well as OCI-AML2 and HNT-34 cells
(both NPM1 wild-type) [37], all of which have detectable
TP53 levels by western blot. In vitro exposure to 6-hour
low-dose dactinomycin resulted in higher TP53 levels in
NPM1-mutated cell lines, compared to NPM1 wild-type
cells (Figs. 4A and S2A).
As we could not discriminate whether higher TP53 levels
in NPM1-mutated cells were secondary to factors other than
just the presence of mutant NPM1, we engineered NPM1
wild-type OCI-AML2 cells to express a doxycycline-
inducible mutant NPM1 fused to the fluorescent protein
ZsGreen1 (ZsGreen1-NPM1c) (Fig. 4B). Engineered cells
were incubated with doxycycline for 10 days and then
treated with pulsed dactinomycin either as bulk or following
sorting for high ZsGreen1-NPM1c levels (Fig. 4B). OCI-
AML2 cells transduced with a doxycycline-inducible
ZsGreen1 empty vector and sorted for high ZsGreen1
levels were used as control. In vitro pulsed dactinomycin
produced higher levels of TP53, its downstream P21 as well
as cleaved poly(ADP-ribose) polymerase (PARP) in cells
expressing mutant NPM1, compared to control. Further-
more, cells expressing the highest ZsGreen-NPM1c levels
showed the strongest TP53 activation and apoptosis
induction at 24 h (Fig. 4C). In conclusion, expression of
NPM1 mutant protein in NPM1 wild-type cells confers
higher sensitivity to dactinomycin as measured by TP53 and
P21 levels, which is proportional to NPM1mut expression
levels.
Altogether, these results support the hypothesis that
NPM1-mutated AML cells have lower thresholds for
dactinomycin-induced nucleolar stress response. However,
the mechanisms through which mutant NPM1 sensitizes
AML cells to dactinomycin remain to be clarified.
Discussion
Here, we report the results of the first phase 2 trial evalu-
ating the safety and efficacy of dactinomycin in r/r NPM1-
mutated AML. The primary endpoint of the study was met
since CR/CRi was obtained in 4/9 evaluable patients. While
three patients who initially responded to the drug relapsed
within seven months, one patient who underwent allo-
HSCT is still in molecular CR > 4 years later. This study
follows the previous report of one NPM1-mutated AML
patient unfit for intensive CHT due to congestive heart
failure, who was successfully treated with single-agent
dactinomycin at the dose of 12.5 μg/Kg/day for 5 days [24].
The patient remains in molecular CR, 6 years following
treatment and is considered cured. Our results suggest that
dactinomycin administered as single-agent in NPM1-muta-
ted r/r patients can induce CR and can be successfully used
to bridge patients to allo-HSCT, although these data need
validation in a larger cohort.
PK studies conducted in these patients generated novel
data demonstrating that dactinomycin clearance values
decrease progressively across the 5 days of treatment. With
the caveat of the limited number of patients, dactinomycin
AUC correlated with toxicity, particularly mucositis, but not
with CR/CRi. These data, along with our previous report [24],
suggest that doses lower than 15 μg/Kg/day (e.g., 10–12.5 μg/
Kg/day for 5 days) could be equally effective but associated
with reduced toxicity. In this regard, a multicenter Phase
2 study to establish the efficacy of dactinomycin 12.5 μg/Kg/
day for 5 days in NPM1-mutated AML patients unfit or
relapsed after hypomethylating agents (HMAs) is currently
Fig. 3 Dactinomycin induces nucleolar stress in NPM1-mutated
AML cells in vitro and in patients. A Immunofluorescence of OCI-
AML3 cells treated with dactinomycin at the indicated concentrations
for 1 h/day for a maximum of 4 consecutive days, stained with an anti-
NPM1, which recognizes both mutant and wild-type NPM1 (tNPM1).
B Western blot analysis of TP53 and β-actin in OCI-AML3 cells
treated with dactinomycin at the indicated concentration for 1 h.
C Viability of OCI-AML3 cells treated with dactinomycin at the
indicated concentration for 1 h/day for 4 consecutive days and studied
by flow cytometry with 7-AAD and Annexin V. Results are expressed
as percentage of 7-AAD/Annexin V double-negative cells (n= 4,
Dunnett’s multiple comparison). D Immunofluorescence of PDX2
cells treated with dactinomycin at the indicated concentrations for 1 h/
day for a maximum of 4 consecutive days, stained with the anti-
tNPM1. E Western blot analysis of TP53 in PDX2 cells treated with
dactinomycin at the indicated concentration for 1 h. F Viability of
PDX2 cells treated with dactinomycin at the indicated concentration
for 1 h/day for 4 consecutive days and studied by flow cytometry with
7-AAD and Annexin V. Results are expressed as percentage of 7-
AAD/Annexin V double-negative cells (n= 4, Dunnett’s multiple
comparison). G Immunofluorescence of cells isolated from the bone
marrow of patient UPN002 before starting the treatment (Pre), 4 h
following the first administration (d1), and 4 h after the fourth
administration (d4). Cells were stained with the anti-tNPM1.
H Western blot analysis of TP53 in cells isolated from the bone
marrow of patient UPN002 before starting the treatment (Pre), 4 h
following the first administration (d1), and 4 h after the fourth
administration (d4). ActD, dactinomycin. *p < 0.05, **p < 0.01,
***p < 0.001. Error bars indicate s.e.m. Scale bar: 10 μm.
I. Gionfriddo et al.
ongoing (EudraCT n.2014-003490-41). Recently, off-label
dactinomycin 12.5 μg/Kg/day for 5 days has been tested in a
heterogeneous group of 26 adult patients with NPM1-mutated
AML (mostly relapsed/refractory), with a reported CR rate of
18% [38]. However, due to the high heterogeneity and the
retrospective fashion of the study, no statistical conclusion on
the efficacy of this dose could be drawn.
Combinations of HMAs and venetoclax have recently
demonstrated high efficacy in unfit older patients with
NPM1-mutated AML, although patients eventually relapse
[16, 39]. Older unfit NPM1-mutated AML patients relap-
sing after venetoclax-based regimens represent a medical
need and dactinomycin could be an inexpensive therapeutic
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Fig. 4 NPM1mut facilitates
nucleolar stress response to
dactinomycin. A Western blot
analysis of TP53, NPM1mut and
wild-type NPM1 (WT NPM1) in
OCI-AML3, IMS-M2, OCI-
AML2, and HNT-34 cells,
treated with dactinomycin at the
indicated concentration (μg/mL)
for 6 h. Quantification of TP53
fold changes is reported. See
also Fig. S2A. B Cartoon
illustrating the design of the
experiment performed on OCI-
AML2 cells engineered to
express doxycycline-inducible
NPM1mut. C Western blot
analysis of NPM1mut, TP53,
P21, and PARP in engineered
OCI-AML2 treated with
dactinomycin 0.05 μg/mL for 1 h
and harvested 3 and 23 h later.
Dox doxycycline. ActD
dactinomycin.
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The mechanisms through which dactinomycin exert its
antileukemic activity is unclear. The finding that NPM1-
mutated cells seem to have lower thresholds for nucleolar
stress response in vitro supports our previous hypothesis
that higher levels of NPM1 in the nucleoplasm may help
trigger dactinomycin-mediated nucleolar stress response,
contributing to the high activity of the drug in NPM1-
mutated AML [24]. Since RNA Pol I inhibition by dacti-
nomycin reduces rRNA concentration in the nucleoli
resulting in loss of NPM1 phase separation from the
nucleoplasm [40], we speculate that in NPM1-mutated cells,
where NPM1 already tends to be delocalized to the
nucleoplasm, dactinomycin may exacerbate such delocali-
zation, stimulating nucleolar stress response. However,
other mechanisms may contribute to the antileukemic
activity of dactinomycin in NPM1-mutated AML (H. de
Thé, unpublished results).
The impact of co-occurring mutations on the sensitivity of
NPM1-mutated cells to dactinomycin could not be established
due to the limited sample size. However, three of the four
patients who achieved CR/CRi carried mutations of either
IDH1 or IDH2. Interestingly, the previously reported NPM1-
mutated patient cured by single-agent dactinomycin also
carried an IDH2 mutation. These data suggest that the com-
bination of IDH and NPM1 mutations may confer sensitivity
to dactinomycin, but this hypothesis needs further validation.
Interestingly, IDH-mutated hematopoietic cells display altered
DNA-damage response with consequent accumulation of
DNA damage [41, 42]. We speculate that this background
may itself facilitate a TP53-mediated response and
dactinomycin-induced nucleolar stress would exacerbate the
activation of TP53 downstream signals. This hypothesis,
which needs to be validated and could be partially indepen-
dent from nucleolar stress, may also explain the promising
sensitivity of IDH/NPM1 double-mutated AML to other
compounds (e.g., venetoclax).
Other drugs causing nucleolar stress through inhibition
of ribosome biogenesis [43] are also worthy of investigation
in NPM1-mutated AML. For instance, anthracyclines, such
as daunorubicin, have been demonstrated to induce
nucleolar stress response coupled with NPM1 relocation to
the nucleoplasm in vitro [22], similar to dactinomycin.
Intriguingly, NPM1-mutated AML shows excellent
response rates to anthracycline-containing regimens [11].
In conclusion, it remains to be established whether: (i)
dactinomycin could be used at lower doses with lower
toxicity and similar efficacy; (ii) dactinomycin may repre-
sent an option for NPM1-mutated AML patients unfit or
older than 75 years refractory to or relapsed after
venetoclax-based regimens; and (iii) combination of dacti-
nomycin with newer agents (e.g., HMAs, venetoclax, FLT3
inhibitors) may yield better results, particularly in NPM1-
mutated patients carrying FLT3-ITD. Furthermore, deeper
understanding of the mechanisms behind nucleolar stress
response and the apparent higher sensitivity of NPM1-
mutated cells to dactinomycin will help optimize new
therapeutic approaches in this setting.
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